Structural Comparative Modeling of Multi-Domain F508del CFTR

被引:10
|
作者
McDonald, Eli Fritz [1 ,2 ]
Woods, Hope [2 ,3 ]
Smith, Shannon T. [2 ,3 ]
Kim, Minsoo [3 ]
Schoeder, Clara T. [1 ,2 ,4 ]
Plate, Lars [1 ,5 ]
Meiler, Jens [1 ,2 ,4 ,6 ,7 ]
机构
[1] Vanderbilt Univ, Dept Chem, Nashville, TN 37235 USA
[2] Vanderbilt Univ, Ctr Struct Biol, Nashville, TN 37235 USA
[3] Vanderbilt Univ, Program Chem & Phys Biol, Nashville, TN 37235 USA
[4] Univ Leipzig, Leipzig Med Sch, D-04109 Leipzig, Germany
[5] Vanderbilt Univ, Dept Biol Sci, Nashville, TN 37235 USA
[6] Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37235 USA
[7] Univ Leipzig, Inst Drug Discovery, D-04109 Leipzig, Germany
关键词
cystic fibrosis; comparative modeling; computational protein modeling; protein folding disease; pharmacological chaperones; VX-809; structure-based drug discovery; TRANSMEMBRANE CONDUCTANCE REGULATOR; NUCLEOTIDE-BINDING DOMAIN; CORRECTOR VX-809; LIGAND DOCKING; MUTATION; NBD1; PREDICTION; MECHANISM; IDENTIFICATION; SIMULATIONS;
D O I
10.3390/biom12030471
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cystic fibrosis (CF) is a rare genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR), an epithelial anion channel expressed in several vital organs. Absence of functional CFTR results in imbalanced osmotic equilibrium and subsequent mucus build up in the lungs-which increases the risk of infection and eventually causes death. CFTR is an ATP-binding cassette (ABC) transporter family protein composed of two transmembrane domains (TMDs), two nucleotide binding domains (NBDs), and an unstructured regulatory domain. The most prevalent patient mutation is the deletion of F508 (F508del), making F508del CFTR the primary target for current FDA approved CF therapies. However, no experimental multi-domain F508del CFTR structure has been determined and few studies have modeled F508del using multi-domain WT CFTR structures. Here, we used cryo-EM density data and Rosetta comparative modeling (RosettaCM) to compare a F508del model with published experimental data on CFTR NBD1 thermodynamics. We then apply this modeling method to generate multi-domain WT and F508del CFTR structural models. These models demonstrate the destabilizing effects of F508del on NBD1 and the NBD1/TMD interface in both the inactive and active conformation of CFTR. Furthermore, we modeled F508del/R1070W and F508del bound to the CFTR corrector VX-809. Our models reveal the stabilizing effects of VX-809 on multi-domain models of F508del CFTR and pave the way for rational design of additional drugs that target F508del CFTR for treatment of CF.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] F508DEL AND I539T MODULATE THE DYNAMICS OF THE FIRST NUCLEOTIDE BINDING DOMAIN OF CFTR
    Chong, P.
    Hudson, R.
    Forman-Kay, J. D.
    PEDIATRIC PULMONOLOGY, 2011, : 223 - 223
  • [22] CFTR FUNCTION MEASUREMENTS IN PLANAR NASAL CULTURES WITH F508DEL/S1159P AND F508DEL/C.850DUPA GENOTYPE
    Illek, B.
    Hari, G.
    Kiles, F.
    Zlock, L.
    Finkbeiner, W.
    McGarry, M. E.
    Ly, N. P.
    Nielson, D. W.
    PEDIATRIC PULMONOLOGY, 2018, 53 : 171 - 172
  • [23] IDENTIFICATION OF EFFICACIOUS F508DEL CFTR CORRECTORS USING A NOVEL HOMOLOGY MODEL
    Aller, S.
    Tang, L.
    Rajpur, J.
    Sloane, P.
    Sorscher, E. J.
    Rowe, S. M.
    PEDIATRIC PULMONOLOGY, 2012, 47 : 226 - 227
  • [24] Synonymous Codon Usage Affects the Expression of Wild Type and F508del CFTR
    Shah, Kapit
    Cheng, Yi
    Hahn, Brian
    Bridges, Robert
    Bradbury, Neil A.
    Mueller, David M.
    JOURNAL OF MOLECULAR BIOLOGY, 2015, 427 (06) : 1464 - 1479
  • [25] EXPRESSION OF PROLYL ENDOPEPTIDASE IN BRONCHIAL EPITHELIAL CELLS: IMPACT OF F508DEL CFTR
    Szul, T.
    Gaggar, A.
    Xu, X.
    PEDIATRIC PULMONOLOGY, 2012, 47 : 261 - 261
  • [26] ABNORMAL MUCUS SECRETION IN MULTIPLE ORGANS OF A MURINE F508DEL CFTR MODEL
    Stolarczyk, M.
    Veltman, M.
    Buys-Offerman, L.
    Touqui, L.
    Scholte, B. J.
    PEDIATRIC PULMONOLOGY, 2014, 49 : 268 - 269
  • [27] Junctional abnormalities in human airway epithelial cells expressing F508del CFTR
    Molina, Samuel A.
    Stauffer, Brandon
    Moriarty, Hannah K.
    Kim, Agnes H.
    McCarty, Nael A.
    Koval, Michael
    AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2015, 309 (05) : L475 - L487
  • [28] Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis
    Sermet-Gaudelus, Isabelle
    Clancy, John P.
    Nichols, David P.
    Nick, Jerry A.
    De Boeck, Kris
    Solomon, George M.
    Mall, Marcus A.
    Bolognese, James
    Bouisset, Florilene
    den Hollander, Wilhelmina
    Paquette-Lamontagne, Nicolas
    Tomkinson, Nigel
    Henig, Noreen
    Elborn, J. Stuart
    Rowe, Steven M.
    JOURNAL OF CYSTIC FIBROSIS, 2019, 18 (04) : 536 - 542
  • [29] CONSTITUTIVE EXPRESSION OF CFTR SUPPRESSOR MUTATIONS AS A TOOL FOR INVESTIGATING F508DEL CORRECTION
    Hong, J. S.
    Tuggle, K. L.
    Wen, H.
    Sorscher, E. J.
    PEDIATRIC PULMONOLOGY, 2013, 48 : 274 - 274
  • [30] Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR
    Veit, Guido
    Vaccarin, Christian
    Lukacs, Gergely L.
    JOURNAL OF CYSTIC FIBROSIS, 2021, 20 (05) : 895 - 898